liraglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| glucagon-like peptide (GLP) analogues and agonists | 4164 | 204656-20-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | U | P |
| 1.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 6 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.01 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| CL (Clearance) | 0.01 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 8.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 2010 | PMDA | Novo Nordisk Pharma Ltd | |
| June 30, 2009 | EMA | ||
| Jan. 25, 2010 | FDA | NOVO NORDISK INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pancreatitis | 2264.11 | 14.58 | 788 | 21258 | 48267 | 63418709 |
| Pancreatitis acute | 690.68 | 14.58 | 283 | 21763 | 26883 | 63440093 |
| Nausea | 562.39 | 14.58 | 1031 | 21015 | 853440 | 62613536 |
| Pancreatic carcinoma | 426.50 | 14.58 | 142 | 21904 | 7486 | 63459490 |
| Diabetic ketoacidosis | 361.28 | 14.58 | 165 | 21881 | 20340 | 63446636 |
| Vomiting | 324.18 | 14.58 | 642 | 21404 | 558975 | 62908001 |
| Lipase increased | 288.88 | 14.58 | 114 | 21932 | 9786 | 63457190 |
| Blood glucose increased | 286.06 | 14.58 | 235 | 21811 | 83521 | 63383455 |
| Eructation | 172.14 | 14.58 | 75 | 21971 | 8258 | 63458718 |
| Injection site urticaria | 171.44 | 14.58 | 88 | 21958 | 13985 | 63452991 |
| Injection site rash | 152.78 | 14.58 | 90 | 21956 | 18719 | 63448257 |
| Abdominal pain | 148.02 | 14.58 | 319 | 21727 | 293137 | 63173839 |
| Cholelithiasis | 145.10 | 14.58 | 121 | 21925 | 43804 | 63423172 |
| Injection site erythema | 143.19 | 14.58 | 160 | 21886 | 83014 | 63383962 |
| Weight decreased | 143.15 | 14.58 | 304 | 21742 | 276494 | 63190482 |
| Pancreatic carcinoma metastatic | 135.59 | 14.58 | 44 | 22002 | 2134 | 63464842 |
| Diabetes mellitus inadequate control | 129.77 | 14.58 | 75 | 21971 | 15051 | 63451925 |
| Glycosylated haemoglobin increased | 124.06 | 14.58 | 68 | 21978 | 12330 | 63454646 |
| Hypoglycaemia | 123.54 | 14.58 | 127 | 21919 | 59938 | 63407038 |
| Injection site pruritus | 114.44 | 14.58 | 107 | 21939 | 45009 | 63421967 |
| Diarrhoea | 109.05 | 14.58 | 513 | 21533 | 714853 | 62752123 |
| Ketoacidosis | 109.01 | 14.58 | 45 | 22001 | 4333 | 63462643 |
| Blood glucose decreased | 105.02 | 14.58 | 74 | 21972 | 20878 | 63446098 |
| Euglycaemic diabetic ketoacidosis | 102.58 | 14.58 | 41 | 22005 | 3633 | 63463343 |
| Lactic acidosis | 99.40 | 14.58 | 92 | 21954 | 38195 | 63428781 |
| Dehydration | 94.81 | 14.58 | 195 | 21851 | 173159 | 63293817 |
| Medullary thyroid cancer | 91.35 | 14.58 | 20 | 22026 | 201 | 63466775 |
| Papillary thyroid cancer | 91.25 | 14.58 | 33 | 22013 | 2223 | 63464753 |
| Amylase increased | 89.99 | 14.58 | 44 | 22002 | 6301 | 63460675 |
| Thyroid mass | 83.64 | 14.58 | 37 | 22009 | 4221 | 63462755 |
| Injection site reaction | 73.51 | 14.58 | 96 | 21950 | 58428 | 63408548 |
| Acute kidney injury | 70.31 | 14.58 | 226 | 21820 | 263189 | 63203787 |
| Weight loss poor | 69.55 | 14.58 | 23 | 22023 | 1184 | 63465792 |
| Adenocarcinoma pancreas | 68.01 | 14.58 | 22 | 22024 | 1056 | 63465920 |
| Abdominal pain upper | 63.33 | 14.58 | 186 | 21860 | 206258 | 63260718 |
| Thyroid neoplasm | 60.40 | 14.58 | 29 | 22017 | 3990 | 63462986 |
| Drug ineffective | 60.28 | 14.58 | 176 | 21870 | 1044589 | 62422387 |
| Systemic lupus erythematosus | 57.06 | 14.58 | 4 | 22042 | 208914 | 63258062 |
| Thyroid cancer | 56.74 | 14.58 | 31 | 22015 | 5580 | 63461396 |
| Decreased appetite | 56.07 | 14.58 | 203 | 21843 | 250849 | 63216127 |
| Impaired gastric emptying | 55.30 | 14.58 | 38 | 22008 | 10294 | 63456682 |
| Glossodynia | 50.10 | 14.58 | 3 | 22043 | 178873 | 63288103 |
| Joint swelling | 48.11 | 14.58 | 27 | 22019 | 327639 | 63139337 |
| Drug dose titration not performed | 46.45 | 14.58 | 14 | 22032 | 531 | 63466445 |
| Constipation | 45.31 | 14.58 | 176 | 21870 | 224767 | 63242209 |
| Injection site haematoma | 43.50 | 14.58 | 28 | 22018 | 6804 | 63460172 |
| Reversible cerebral vasoconstriction syndrome | 42.45 | 14.58 | 20 | 22026 | 2638 | 63464338 |
| Pancreatic neoplasm | 42.12 | 14.58 | 14 | 22032 | 732 | 63466244 |
| Arthropathy | 41.24 | 14.58 | 15 | 22031 | 234777 | 63232199 |
| Flatulence | 40.60 | 14.58 | 55 | 21991 | 34647 | 63432329 |
| Cholecystitis | 39.99 | 14.58 | 37 | 22009 | 15340 | 63451636 |
| Abdominal distension | 39.91 | 14.58 | 91 | 21955 | 86524 | 63380452 |
| Infusion related reaction | 39.36 | 14.58 | 18 | 22028 | 245503 | 63221473 |
| Pain | 38.86 | 14.58 | 130 | 21916 | 740498 | 62726478 |
| Pyrexia | 38.68 | 14.58 | 65 | 21981 | 470413 | 62996563 |
| Treatment failure | 37.98 | 14.58 | 11 | 22035 | 199032 | 63267944 |
| Drug intolerance | 37.86 | 14.58 | 31 | 22015 | 308630 | 63158346 |
| Rheumatoid arthritis | 35.70 | 14.58 | 22 | 22024 | 253797 | 63213179 |
| Pericarditis | 34.56 | 14.58 | 3 | 22043 | 131576 | 63335400 |
| Pancreatic enzymes increased | 34.04 | 14.58 | 12 | 22034 | 750 | 63466226 |
| Therapeutic product effect decreased | 32.82 | 14.58 | 13 | 22033 | 193174 | 63273802 |
| Cholecystitis acute | 32.01 | 14.58 | 25 | 22021 | 8235 | 63458741 |
| Pancreatic mass | 31.72 | 14.58 | 12 | 22034 | 917 | 63466059 |
| Hyperglycaemia | 31.43 | 14.58 | 54 | 21992 | 41813 | 63425163 |
| Neutropenia | 31.02 | 14.58 | 11 | 22035 | 174994 | 63291982 |
| Injection site pain | 30.67 | 14.58 | 107 | 21939 | 129693 | 63337283 |
| Drug titration error | 29.44 | 14.58 | 11 | 22035 | 812 | 63466164 |
| Pancreatic cyst | 28.78 | 14.58 | 13 | 22033 | 1557 | 63465419 |
| Palpitations | 25.81 | 14.58 | 92 | 21954 | 112678 | 63354298 |
| Mental disability | 25.64 | 14.58 | 6 | 22040 | 83 | 63466893 |
| Febrile neutropenia | 25.62 | 14.58 | 5 | 22041 | 118444 | 63348532 |
| Glycosylated haemoglobin decreased | 25.62 | 14.58 | 9 | 22037 | 557 | 63466419 |
| Goitre | 25.20 | 14.58 | 19 | 22027 | 5942 | 63461034 |
| Pancreatitis necrotising | 24.66 | 14.58 | 12 | 22034 | 1700 | 63465276 |
| Infection | 24.56 | 14.58 | 26 | 22020 | 229147 | 63237829 |
| Completed suicide | 24.41 | 14.58 | 10 | 22036 | 145663 | 63321313 |
| General physical health deterioration | 23.73 | 14.58 | 21 | 22025 | 201381 | 63265595 |
| Renal failure | 23.60 | 14.58 | 92 | 21954 | 117560 | 63349416 |
| Swelling | 23.57 | 14.58 | 37 | 22009 | 275341 | 63191635 |
| Bile duct stone | 23.32 | 14.58 | 15 | 22031 | 3641 | 63463335 |
| Ductal adenocarcinoma of pancreas | 23.07 | 14.58 | 6 | 22040 | 131 | 63466845 |
| Disease progression | 23.01 | 14.58 | 7 | 22039 | 122751 | 63344225 |
| Hypoglycaemic unconsciousness | 22.84 | 14.58 | 9 | 22037 | 768 | 63466208 |
| Haemoglobin decreased | 22.79 | 14.58 | 11 | 22035 | 145474 | 63321502 |
| Blood glucose abnormal | 22.50 | 14.58 | 20 | 22026 | 7872 | 63459104 |
| Helicobacter infection | 22.12 | 14.58 | 3 | 22043 | 92782 | 63374194 |
| Wound | 21.79 | 14.58 | 15 | 22031 | 163248 | 63303728 |
| Blister | 21.61 | 14.58 | 9 | 22037 | 129805 | 63337171 |
| Maternal exposure during pregnancy | 21.38 | 14.58 | 27 | 22019 | 220035 | 63246941 |
| Toxicity to various agents | 21.37 | 14.58 | 33 | 22013 | 247217 | 63219759 |
| Bile acid malabsorption | 21.35 | 14.58 | 6 | 22040 | 177 | 63466799 |
| Stomatitis | 20.96 | 14.58 | 11 | 22035 | 138714 | 63328262 |
| Huerthle cell carcinoma | 20.90 | 14.58 | 3 | 22043 | 0 | 63466976 |
| Lack of satiety | 20.90 | 14.58 | 3 | 22043 | 0 | 63466976 |
| Pancreatic operation | 20.90 | 14.58 | 3 | 22043 | 0 | 63466976 |
| Musculoskeletal stiffness | 20.86 | 14.58 | 20 | 22026 | 184598 | 63282378 |
| C-reactive protein increased | 20.48 | 14.58 | 4 | 22042 | 94703 | 63372273 |
| Injection site bruising | 20.37 | 14.58 | 45 | 22001 | 41865 | 63425111 |
| Injection site nodule | 20.27 | 14.58 | 14 | 22032 | 3821 | 63463155 |
| Genotype drug resistance test positive | 20.04 | 14.58 | 7 | 22039 | 426 | 63466550 |
| Glomerular filtration rate decreased | 19.98 | 14.58 | 24 | 22022 | 13417 | 63453559 |
| Incision site swelling | 19.97 | 14.58 | 6 | 22040 | 225 | 63466751 |
| White blood cell count decreased | 19.62 | 14.58 | 12 | 22034 | 139092 | 63327884 |
| Blood calcitonin increased | 19.43 | 14.58 | 4 | 22042 | 29 | 63466947 |
| Gastritis | 19.21 | 14.58 | 41 | 22005 | 37262 | 63429714 |
| Pancytopenia | 19.14 | 14.58 | 5 | 22041 | 96928 | 63370048 |
| Increased appetite | 19.12 | 14.58 | 20 | 22026 | 9610 | 63457366 |
| Cholangiocarcinoma | 19.12 | 14.58 | 9 | 22037 | 1185 | 63465791 |
| Hepatic steatosis | 18.89 | 14.58 | 35 | 22011 | 28734 | 63438242 |
| Aerococcus urinae infection | 18.82 | 14.58 | 3 | 22043 | 3 | 63466973 |
| Injection site swelling | 18.69 | 14.58 | 47 | 21999 | 47525 | 63419451 |
| Pneumonia | 18.30 | 14.58 | 89 | 21957 | 456678 | 63010298 |
| Pancreatic pseudocyst | 17.83 | 14.58 | 7 | 22039 | 591 | 63466385 |
| Cholecystectomy | 17.42 | 14.58 | 20 | 22026 | 10657 | 63456319 |
| Impaired healing | 17.24 | 14.58 | 7 | 22039 | 102535 | 63364441 |
| Dysgeusia | 17.16 | 14.58 | 45 | 22001 | 46665 | 63420311 |
| Breast cancer | 17.15 | 14.58 | 46 | 22000 | 48337 | 63418639 |
| Anaemia | 17.08 | 14.58 | 49 | 21997 | 293381 | 63173595 |
| Malignant neoplasm progression | 16.67 | 14.58 | 4 | 22042 | 82117 | 63384859 |
| Benign neoplasm of thyroid gland | 16.52 | 14.58 | 8 | 22038 | 1121 | 63465855 |
| Anuria | 16.39 | 14.58 | 21 | 22025 | 12530 | 63454446 |
| Biliary colic | 16.34 | 14.58 | 12 | 22034 | 3605 | 63463371 |
| Injection site cyst | 16.27 | 14.58 | 4 | 22042 | 69 | 63466907 |
| Death | 16.14 | 14.58 | 71 | 21975 | 374310 | 63092666 |
| Diabetic retinopathy | 15.97 | 14.58 | 10 | 22036 | 2317 | 63464659 |
| Gastroenteritis | 15.79 | 14.58 | 31 | 22015 | 26559 | 63440417 |
| Discomfort | 15.77 | 14.58 | 21 | 22025 | 167353 | 63299623 |
| Metabolic alkalosis | 15.77 | 14.58 | 11 | 22035 | 3050 | 63463926 |
| Somnambulism | 15.71 | 14.58 | 14 | 22032 | 5529 | 63461447 |
| Hepatic enzyme increased | 15.63 | 14.58 | 29 | 22017 | 202299 | 63264677 |
| Diabetic neuropathy | 15.36 | 14.58 | 12 | 22034 | 3952 | 63463024 |
| Lower respiratory tract infection | 15.33 | 14.58 | 14 | 22032 | 132293 | 63334683 |
| Thrombocytopenia | 15.25 | 14.58 | 18 | 22028 | 151139 | 63315837 |
| Imminent abortion | 15.21 | 14.58 | 3 | 22043 | 17 | 63466959 |
| Arthralgia | 15.11 | 14.58 | 126 | 21920 | 569584 | 62897392 |
| Diabetic ketosis | 14.87 | 14.58 | 5 | 22041 | 271 | 63466705 |
| Gastrooesophageal reflux disease | 14.70 | 14.58 | 69 | 21977 | 95570 | 63371406 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pancreatitis | 1772.19 | 15.40 | 661 | 15024 | 38230 | 34903016 |
| Pancreatitis acute | 516.86 | 15.40 | 252 | 15433 | 27889 | 34913357 |
| Pancreatic carcinoma | 420.49 | 15.40 | 156 | 15529 | 8745 | 34932501 |
| Nausea | 343.69 | 15.40 | 573 | 15112 | 339335 | 34601911 |
| Diabetic ketoacidosis | 305.54 | 15.40 | 153 | 15532 | 17879 | 34923367 |
| Pancreatic carcinoma metastatic | 225.49 | 15.40 | 74 | 15611 | 2866 | 34938380 |
| Lipase increased | 214.62 | 15.40 | 98 | 15587 | 9318 | 34931928 |
| Blood glucose increased | 188.16 | 15.40 | 188 | 15497 | 66530 | 34874716 |
| Vomiting | 166.89 | 15.40 | 352 | 15333 | 247269 | 34693977 |
| Glycosylated haemoglobin increased | 137.33 | 15.40 | 77 | 15608 | 11283 | 34929963 |
| Diabetes mellitus inadequate control | 132.89 | 15.40 | 80 | 15605 | 13384 | 34927862 |
| Adenocarcinoma pancreas | 111.08 | 15.40 | 36 | 15649 | 1338 | 34939908 |
| Weight decreased | 102.96 | 15.40 | 237 | 15448 | 176064 | 34765182 |
| Cholelithiasis | 98.07 | 15.40 | 79 | 15606 | 21069 | 34920177 |
| Abdominal pain | 93.35 | 15.40 | 218 | 15467 | 163400 | 34777846 |
| Eructation | 88.54 | 15.40 | 43 | 15642 | 4688 | 34936558 |
| Amylase increased | 84.71 | 15.40 | 45 | 15640 | 5923 | 34935323 |
| Diarrhoea | 81.79 | 15.40 | 368 | 15317 | 389544 | 34551702 |
| Lactic acidosis | 78.28 | 15.40 | 87 | 15598 | 34685 | 34906561 |
| Injection site rash | 72.50 | 15.40 | 36 | 15649 | 4117 | 34937129 |
| Acute kidney injury | 66.93 | 15.40 | 292 | 15393 | 304696 | 34636550 |
| Hypoglycaemia | 66.70 | 15.40 | 101 | 15584 | 54539 | 34886707 |
| Papillary thyroid cancer | 64.30 | 15.40 | 20 | 15665 | 649 | 34940597 |
| Toxicity to various agents | 62.76 | 15.40 | 8 | 15677 | 200354 | 34740892 |
| Pancreatitis necrotising | 60.60 | 15.40 | 28 | 15657 | 2730 | 34938516 |
| Ketoacidosis | 60.23 | 15.40 | 32 | 15653 | 4211 | 34937035 |
| Abdominal pain upper | 56.60 | 15.40 | 109 | 15576 | 71381 | 34869865 |
| Thyroid cancer | 52.99 | 15.40 | 22 | 15663 | 1658 | 34939588 |
| Medullary thyroid cancer | 46.12 | 15.40 | 9 | 15676 | 35 | 34941211 |
| Weight loss poor | 46.04 | 15.40 | 12 | 15673 | 202 | 34941044 |
| Metastases to liver | 43.08 | 15.40 | 41 | 15644 | 13622 | 34927624 |
| Injection site haematoma | 41.97 | 15.40 | 19 | 15666 | 1766 | 34939480 |
| Respiratory tract haemorrhage | 41.30 | 15.40 | 17 | 15668 | 1253 | 34939993 |
| Pancreatitis chronic | 40.83 | 15.40 | 20 | 15665 | 2220 | 34939026 |
| Pancreatic neoplasm | 39.50 | 15.40 | 15 | 15670 | 893 | 34940353 |
| Thyroid mass | 39.33 | 15.40 | 13 | 15672 | 514 | 34940732 |
| Febrile neutropenia | 39.30 | 15.40 | 7 | 15678 | 136842 | 34804404 |
| Injection site erythema | 37.87 | 15.40 | 41 | 15644 | 15858 | 34925388 |
| Dyspepsia | 36.69 | 15.40 | 62 | 15623 | 36670 | 34904576 |
| Injection site pruritus | 36.48 | 15.40 | 28 | 15657 | 6955 | 34934291 |
| Neutropenia | 35.50 | 15.40 | 13 | 15672 | 156765 | 34784481 |
| Gastrooesophageal reflux disease | 35.25 | 15.40 | 62 | 15623 | 37862 | 34903384 |
| Dehydration | 34.32 | 15.40 | 132 | 15553 | 129837 | 34811409 |
| Pancreatic pseudocyst | 33.31 | 15.40 | 13 | 15672 | 834 | 34940412 |
| Pneumonia | 33.10 | 15.40 | 71 | 15614 | 362556 | 34578690 |
| Pancreatic mass | 32.49 | 15.40 | 13 | 15672 | 891 | 34940355 |
| Death | 32.29 | 15.40 | 83 | 15602 | 397966 | 34543280 |
| Product use in unapproved indication | 31.65 | 15.40 | 7 | 15678 | 117492 | 34823754 |
| Blood glucose decreased | 31.29 | 15.40 | 34 | 15651 | 13203 | 34928043 |
| Decreased appetite | 30.92 | 15.40 | 152 | 15533 | 166240 | 34775006 |
| Cholangiocarcinoma | 30.59 | 15.40 | 14 | 15671 | 1335 | 34939911 |
| Abdominal discomfort | 30.01 | 15.40 | 76 | 15609 | 59759 | 34881487 |
| Pancreatic carcinoma stage IV | 29.52 | 15.40 | 13 | 15672 | 1132 | 34940114 |
| Drug ineffective | 29.37 | 15.40 | 106 | 15579 | 456645 | 34484601 |
| Tonsillar ulcer | 29.30 | 15.40 | 8 | 15677 | 162 | 34941084 |
| Constipation | 28.25 | 15.40 | 129 | 15556 | 136853 | 34804393 |
| Cholecystectomy | 28.16 | 15.40 | 17 | 15668 | 2853 | 34938393 |
| Diabetic metabolic decompensation | 27.00 | 15.40 | 14 | 15671 | 1752 | 34939494 |
| Pyrexia | 25.79 | 15.40 | 71 | 15614 | 332942 | 34608304 |
| Thyroid neoplasm | 25.32 | 15.40 | 9 | 15676 | 444 | 34940802 |
| Thrombocytopenia | 25.10 | 15.40 | 20 | 15665 | 156227 | 34785019 |
| White blood cell count decreased | 25.08 | 15.40 | 6 | 15679 | 95439 | 34845807 |
| Ketosis | 24.49 | 15.40 | 9 | 15676 | 489 | 34940757 |
| Blood calcitonin increased | 24.44 | 15.40 | 5 | 15680 | 26 | 34941220 |
| Platelet count decreased | 23.79 | 15.40 | 12 | 15673 | 119705 | 34821541 |
| Glycosylated haemoglobin decreased | 22.82 | 15.40 | 8 | 15677 | 379 | 34940867 |
| Flatulence | 22.80 | 15.40 | 37 | 15648 | 21161 | 34920085 |
| Disease progression | 22.75 | 15.40 | 10 | 15675 | 108067 | 34833179 |
| Pancreatic enzymes increased | 22.13 | 15.40 | 9 | 15676 | 643 | 34940603 |
| Thyroid adenoma | 21.83 | 15.40 | 4 | 15681 | 10 | 34941236 |
| Injection site reaction | 21.72 | 15.40 | 28 | 15657 | 13005 | 34928241 |
| Euglycaemic diabetic ketoacidosis | 21.54 | 15.40 | 15 | 15670 | 3207 | 34938039 |
| Pancreatic cyst | 20.49 | 15.40 | 9 | 15676 | 779 | 34940467 |
| Acinar cell carcinoma of pancreas | 20.13 | 15.40 | 3 | 15682 | 0 | 34941246 |
| Injection site urticaria | 19.63 | 15.40 | 12 | 15673 | 2060 | 34939186 |
| Cholecystitis chronic | 19.44 | 15.40 | 9 | 15676 | 881 | 34940365 |
| Extrasystoles | 19.25 | 15.40 | 15 | 15670 | 3808 | 34937438 |
| Ludwig angina | 19.13 | 15.40 | 6 | 15679 | 200 | 34941046 |
| Skin wound | 18.86 | 15.40 | 7 | 15678 | 391 | 34940855 |
| Malignant neoplasm progression | 18.76 | 15.40 | 8 | 15677 | 88038 | 34853208 |
| Impaired gastric emptying | 18.37 | 15.40 | 14 | 15671 | 3439 | 34937807 |
| Pancreatectomy | 18.18 | 15.40 | 4 | 15681 | 31 | 34941215 |
| Supraventricular extrasystoles | 18.18 | 15.40 | 14 | 15671 | 3494 | 34937752 |
| Follicular thyroid cancer | 18.05 | 15.40 | 3 | 15682 | 3 | 34941243 |
| Joint swelling | 17.31 | 15.40 | 3 | 15682 | 59887 | 34881359 |
| Ductal adenocarcinoma of pancreas | 17.27 | 15.40 | 4 | 15681 | 40 | 34941206 |
| Gallbladder enlargement | 17.26 | 15.40 | 9 | 15676 | 1139 | 34940107 |
| Catheter site cellulitis | 17.17 | 15.40 | 5 | 15680 | 129 | 34941117 |
| Breath odour | 16.32 | 15.40 | 8 | 15677 | 889 | 34940357 |
| Injection site atrophy | 16.17 | 15.40 | 4 | 15681 | 54 | 34941192 |
| Drug dose titration not performed | 16.15 | 15.40 | 6 | 15679 | 336 | 34940910 |
| Cholecystitis acute | 16.02 | 15.40 | 17 | 15668 | 6422 | 34934824 |
| Gallbladder disorder | 15.80 | 15.40 | 17 | 15668 | 6525 | 34934721 |
| Hyperglycaemia | 15.64 | 15.40 | 46 | 15639 | 39434 | 34901812 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pancreatitis | 2294.96 | 13.57 | 880 | 28074 | 67695 | 79647739 |
| Pancreatitis acute | 933.02 | 13.57 | 423 | 28531 | 49181 | 79666253 |
| Nausea | 636.01 | 13.57 | 1191 | 27763 | 956005 | 78759429 |
| Diabetic ketoacidosis | 587.96 | 13.57 | 274 | 28680 | 33848 | 79681586 |
| Pancreatic carcinoma | 535.09 | 13.57 | 197 | 28757 | 13380 | 79702054 |
| Vomiting | 386.47 | 13.57 | 785 | 28169 | 665043 | 79050391 |
| Lipase increased | 336.48 | 13.57 | 149 | 28805 | 16317 | 79699117 |
| Blood glucose increased | 328.63 | 13.57 | 297 | 28657 | 114678 | 79600756 |
| Pancreatic carcinoma metastatic | 235.11 | 13.57 | 77 | 28877 | 3676 | 79711758 |
| Diabetes mellitus inadequate control | 212.95 | 13.57 | 124 | 28830 | 24140 | 79691294 |
| Eructation | 192.07 | 13.57 | 89 | 28865 | 10820 | 79704614 |
| Lactic acidosis | 189.62 | 13.57 | 176 | 28778 | 70183 | 79645251 |
| Glycosylated haemoglobin increased | 183.90 | 13.57 | 104 | 28850 | 19156 | 79696278 |
| Cholelithiasis | 180.46 | 13.57 | 151 | 28803 | 52513 | 79662921 |
| Weight decreased | 172.84 | 13.57 | 391 | 28563 | 354807 | 79360627 |
| Diarrhoea | 171.63 | 13.57 | 701 | 28253 | 879788 | 78835646 |
| Abdominal pain | 171.19 | 13.57 | 412 | 28542 | 389157 | 79326277 |
| Ketoacidosis | 169.90 | 13.57 | 74 | 28880 | 7780 | 79707654 |
| Hypoglycaemia | 148.96 | 13.57 | 184 | 28770 | 101410 | 79614024 |
| Acute kidney injury | 148.24 | 13.57 | 469 | 28485 | 518935 | 79196499 |
| Adenocarcinoma pancreas | 144.86 | 13.57 | 46 | 28908 | 1987 | 79713447 |
| Injection site erythema | 123.35 | 13.57 | 147 | 28807 | 78050 | 79637384 |
| Euglycaemic diabetic ketoacidosis | 120.98 | 13.57 | 56 | 28898 | 6788 | 79708646 |
| Injection site urticaria | 119.05 | 13.57 | 68 | 28886 | 12758 | 79702676 |
| Papillary thyroid cancer | 118.60 | 13.57 | 42 | 28912 | 2544 | 79712890 |
| Amylase increased | 116.47 | 13.57 | 64 | 28890 | 11145 | 79704289 |
| Injection site rash | 98.03 | 13.57 | 68 | 28886 | 17886 | 79697548 |
| Decreased appetite | 90.90 | 13.57 | 302 | 28652 | 342116 | 79373318 |
| Injection site pruritus | 88.18 | 13.57 | 92 | 28862 | 42191 | 79673243 |
| Medullary thyroid cancer | 86.40 | 13.57 | 20 | 28934 | 251 | 79715183 |
| Pancreatitis necrotising | 85.10 | 13.57 | 37 | 28917 | 3871 | 79711563 |
| Injection site haematoma | 83.77 | 13.57 | 39 | 28915 | 4788 | 79710646 |
| Blood glucose decreased | 81.21 | 13.57 | 71 | 28883 | 26163 | 79689271 |
| Dehydration | 80.73 | 13.57 | 235 | 28719 | 247952 | 79467482 |
| Abdominal pain upper | 72.84 | 13.57 | 212 | 28742 | 223607 | 79491827 |
| Toxicity to various agents | 60.96 | 13.57 | 39 | 28915 | 421501 | 79293933 |
| Weight loss poor | 59.72 | 13.57 | 21 | 28933 | 1245 | 79714189 |
| Joint swelling | 57.02 | 13.57 | 17 | 28937 | 288629 | 79426805 |
| Pancreatic neoplasm | 56.58 | 13.57 | 21 | 28933 | 1455 | 79713979 |
| Thyroid mass | 53.44 | 13.57 | 27 | 28927 | 3963 | 79711471 |
| Neutropenia | 53.21 | 13.57 | 19 | 28935 | 287691 | 79427743 |
| Drug ineffective | 53.00 | 13.57 | 208 | 28746 | 1080705 | 78634729 |
| Febrile neutropenia | 52.70 | 13.57 | 10 | 28944 | 230989 | 79484445 |
| Injection site reaction | 51.29 | 13.57 | 80 | 28874 | 54705 | 79660729 |
| Thyroid neoplasm | 50.10 | 13.57 | 24 | 28930 | 3140 | 79712294 |
| Hyperglycaemia | 48.98 | 13.57 | 90 | 28864 | 70245 | 79645189 |
| Impaired gastric emptying | 46.87 | 13.57 | 35 | 28919 | 10318 | 79705116 |
| Constipation | 46.69 | 13.57 | 215 | 28739 | 282835 | 79432599 |
| Flatulence | 46.58 | 13.57 | 67 | 28887 | 42657 | 79672777 |
| Pyrexia | 45.63 | 13.57 | 113 | 28841 | 678596 | 79036838 |
| Treatment failure | 44.38 | 13.57 | 5 | 28949 | 170481 | 79544953 |
| Drug abuse | 44.35 | 13.57 | 4 | 28950 | 162687 | 79552747 |
| Pancreatic pseudocyst | 43.22 | 13.57 | 17 | 28937 | 1380 | 79714054 |
| Cholangiocarcinoma | 42.72 | 13.57 | 20 | 28934 | 2486 | 79712948 |
| Infusion related reaction | 41.22 | 13.57 | 16 | 28938 | 230221 | 79485213 |
| Cholecystitis acute | 40.81 | 13.57 | 36 | 28918 | 13415 | 79702019 |
| Abdominal distension | 40.48 | 13.57 | 115 | 28839 | 119535 | 79595899 |
| Drug dose titration not performed | 40.38 | 13.57 | 14 | 28940 | 796 | 79714638 |
| Respiratory tract haemorrhage | 38.85 | 13.57 | 17 | 28937 | 1806 | 79713628 |
| Pancreatitis chronic | 36.47 | 13.57 | 21 | 28933 | 3998 | 79711436 |
| Dyspepsia | 35.35 | 13.57 | 103 | 28851 | 108584 | 79606850 |
| Thyroid cancer | 34.88 | 13.57 | 23 | 28931 | 5565 | 79709869 |
| Glycosylated haemoglobin decreased | 34.48 | 13.57 | 12 | 28942 | 690 | 79714744 |
| White blood cell count decreased | 33.84 | 13.57 | 13 | 28941 | 188275 | 79527159 |
| Reversible cerebral vasoconstriction syndrome | 33.26 | 13.57 | 18 | 28936 | 3039 | 79712395 |
| Thrombocytopenia | 32.58 | 13.57 | 29 | 28925 | 265230 | 79450204 |
| Completed suicide | 32.50 | 13.57 | 25 | 28929 | 245742 | 79469692 |
| Bile duct stone | 32.47 | 13.57 | 22 | 28932 | 5567 | 79709867 |
| Ketosis | 32.38 | 13.57 | 13 | 28941 | 1113 | 79714321 |
| Pneumonia | 32.26 | 13.57 | 127 | 28827 | 660119 | 79055315 |
| Pancreatic mass | 31.73 | 13.57 | 14 | 28940 | 1517 | 79713917 |
| Contraindicated product administered | 31.60 | 13.57 | 9 | 28945 | 157529 | 79557905 |
| Pain | 31.53 | 13.57 | 140 | 28814 | 703662 | 79011772 |
| Drug intolerance | 31.11 | 13.57 | 30 | 28924 | 264089 | 79451345 |
| Platelet count decreased | 30.96 | 13.57 | 16 | 28938 | 194648 | 79520786 |
| Rheumatoid arthritis | 29.13 | 13.57 | 20 | 28934 | 208450 | 79506984 |
| Cholecystitis | 28.98 | 13.57 | 38 | 28916 | 22174 | 79693260 |
| Leukopenia | 28.90 | 13.57 | 4 | 28950 | 116509 | 79598925 |
| Disease progression | 28.09 | 13.57 | 16 | 28938 | 184346 | 79531088 |
| Death | 27.64 | 13.57 | 109 | 28845 | 566405 | 79149029 |
| Haemoglobin decreased | 27.62 | 13.57 | 24 | 28930 | 222095 | 79493339 |
| Blood glucose abnormal | 27.60 | 13.57 | 26 | 28928 | 10540 | 79704894 |
| Arthropathy | 27.51 | 13.57 | 15 | 28939 | 177096 | 79538338 |
| Glossodynia | 26.96 | 13.57 | 3 | 28951 | 103334 | 79612100 |
| Pancreatic carcinoma stage IV | 26.91 | 13.57 | 14 | 28940 | 2184 | 79713250 |
| Pancreatic enzymes increased | 26.74 | 13.57 | 12 | 28942 | 1353 | 79714081 |
| Gastrooesophageal reflux disease | 26.73 | 13.57 | 91 | 28863 | 104155 | 79611279 |
| Metastases to liver | 26.01 | 13.57 | 41 | 28913 | 28273 | 79687161 |
| Pemphigus | 25.71 | 13.57 | 3 | 28951 | 99579 | 79615855 |
| Pancreatic cyst | 25.45 | 13.57 | 13 | 28941 | 1952 | 79713482 |
| Drug titration error | 25.29 | 13.57 | 11 | 28943 | 1151 | 79714283 |
| Therapeutic product effect decreased | 25.28 | 13.57 | 14 | 28940 | 163849 | 79551585 |
| Neutrophil count decreased | 23.84 | 13.57 | 3 | 28951 | 93956 | 79621478 |
| Tonsillar ulcer | 23.63 | 13.57 | 8 | 28946 | 423 | 79715011 |
| Malignant neoplasm progression | 23.43 | 13.57 | 10 | 28944 | 135980 | 79579454 |
| Anaemia | 23.40 | 13.57 | 83 | 28871 | 444932 | 79270502 |
| Injection site pain | 23.15 | 13.57 | 101 | 28853 | 129737 | 79585697 |
| Blood calcitonin increased | 23.11 | 13.57 | 5 | 28949 | 45 | 79715389 |
| Arthralgia | 23.08 | 13.57 | 118 | 28836 | 571685 | 79143749 |
| C-reactive protein increased | 23.03 | 13.57 | 9 | 28945 | 129018 | 79586416 |
| Injection site hypersensitivity | 22.82 | 13.57 | 12 | 28942 | 1913 | 79713521 |
| Ductal adenocarcinoma of pancreas | 21.74 | 13.57 | 6 | 28948 | 158 | 79715276 |
| Diabetic metabolic decompensation | 21.49 | 13.57 | 14 | 28940 | 3318 | 79712116 |
| Breath odour | 21.33 | 13.57 | 11 | 28943 | 1685 | 79713749 |
| Goitre | 21.30 | 13.57 | 17 | 28937 | 5522 | 79709912 |
| Glomerular filtration rate decreased | 21.03 | 13.57 | 33 | 28921 | 22669 | 79692765 |
| Benign neoplasm of thyroid gland | 20.91 | 13.57 | 9 | 28945 | 918 | 79714516 |
| Product contamination with body fluid | 20.76 | 13.57 | 3 | 28951 | 0 | 79715434 |
| Pleural effusion | 20.20 | 13.57 | 14 | 28940 | 145248 | 79570186 |
| Thyroid cyst | 20.15 | 13.57 | 7 | 28947 | 400 | 79715034 |
| Bile acid malabsorption | 20.02 | 13.57 | 6 | 28948 | 213 | 79715221 |
| Injection site nodule | 19.89 | 13.57 | 14 | 28940 | 3766 | 79711668 |
| Injection site irritation | 19.86 | 13.57 | 14 | 28940 | 3776 | 79711658 |
| Increased appetite | 19.66 | 13.57 | 23 | 28931 | 11955 | 79703479 |
| Gastroenteritis | 19.32 | 13.57 | 40 | 28914 | 34042 | 79681392 |
| Pericarditis | 19.05 | 13.57 | 7 | 28947 | 104229 | 79611205 |
| Hypoglycaemic unconsciousness | 18.81 | 13.57 | 9 | 28945 | 1174 | 79714260 |
| Cholecystectomy | 18.72 | 13.57 | 20 | 28934 | 9412 | 79706022 |
| Aerococcus urinae infection | 18.69 | 13.57 | 3 | 28951 | 3 | 79715431 |
| Ludwig angina | 18.63 | 13.57 | 6 | 28948 | 271 | 79715163 |
| Cancer surgery | 18.36 | 13.57 | 8 | 28946 | 841 | 79714593 |
| Hyperlipasaemia | 18.31 | 13.57 | 9 | 28945 | 1245 | 79714189 |
| Musculoskeletal stiffness | 18.24 | 13.57 | 22 | 28932 | 174986 | 79540448 |
| Hyperkalaemia | 18.16 | 13.57 | 86 | 28868 | 114312 | 79601122 |
| Incision site swelling | 18.09 | 13.57 | 6 | 28948 | 298 | 79715136 |
| Obstructive pancreatitis | 18.00 | 13.57 | 8 | 28946 | 882 | 79714552 |
| Palpitations | 17.84 | 13.57 | 92 | 28862 | 126518 | 79588916 |
| Nasopharyngitis | 17.21 | 13.57 | 42 | 28912 | 253839 | 79461595 |
| Biliary colic | 17.06 | 13.57 | 13 | 28941 | 3949 | 79711485 |
| Pancreatic neuroendocrine tumour | 16.71 | 13.57 | 7 | 28947 | 668 | 79714766 |
| Blood glucose fluctuation | 16.61 | 13.57 | 16 | 28938 | 6666 | 79708768 |
| Hepatic steatosis | 16.57 | 13.57 | 40 | 28914 | 37698 | 79677736 |
| Infection | 16.37 | 13.57 | 40 | 28914 | 241672 | 79473762 |
| Blood ketone body increased | 16.26 | 13.57 | 7 | 28947 | 715 | 79714719 |
| Product quality issue | 16.01 | 13.57 | 37 | 28917 | 33903 | 79681531 |
| Lower respiratory tract infection | 16.01 | 13.57 | 14 | 28940 | 129206 | 79586228 |
| Gastrointestinal haemorrhage | 16.00 | 13.57 | 18 | 28936 | 147701 | 79567733 |
| Imminent abortion | 15.94 | 13.57 | 3 | 28951 | 12 | 79715422 |
| Helicobacter infection | 15.92 | 13.57 | 3 | 28951 | 69701 | 79645733 |
| Diabetic neuropathy | 15.67 | 13.57 | 15 | 28939 | 6201 | 79709233 |
| Extrasystoles | 15.20 | 13.57 | 16 | 28938 | 7403 | 79708031 |
| Diabetic ketosis | 15.17 | 13.57 | 6 | 28948 | 494 | 79714940 |
| Electrocardiogram QT prolonged | 15.01 | 13.57 | 7 | 28947 | 90379 | 79625055 |
| Urogenital infection fungal | 14.79 | 13.57 | 3 | 28951 | 19 | 79715415 |
| Somnambulism | 14.79 | 13.57 | 14 | 28940 | 5707 | 79709727 |
| Dysgeusia | 14.72 | 13.57 | 50 | 28904 | 57127 | 79658307 |
| General physical health deterioration | 14.67 | 13.57 | 51 | 28903 | 275187 | 79440247 |
| Device malfunction | 14.36 | 13.57 | 27 | 28927 | 21421 | 79694013 |
| Supraventricular extrasystoles | 14.20 | 13.57 | 15 | 28939 | 6972 | 79708462 |
| Pancytopenia | 14.14 | 13.57 | 24 | 28930 | 165721 | 79549713 |
| Anti factor V antibody positive | 14.07 | 13.57 | 3 | 28951 | 25 | 79715409 |
| Hyperchlorhydria | 14.06 | 13.57 | 9 | 28945 | 2070 | 79713364 |
| Medication error | 13.61 | 13.57 | 4 | 28950 | 68638 | 79646796 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10AE56 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting |
| ATC | A10BJ02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues |
| FDA CS | M0160181 | Glucagon-Like Peptide 1 |
| FDA MoA | N0000020058 | Glucagon-like Peptide-1 (GLP-1) Agonists |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D007004 | Hypoglycemic Agents |
| MeSH PA | D054795 | Incretins |
| FDA EPC | N0000178480 | GLP-1 Receptor Agonist |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
| CHEBI has role | CHEBI:71196 | GLP-1 receptor agonist |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Weight loss | indication | 89362005 | |
| Disorder of thyroid gland | contraindication | 14304000 | DOID:50 |
| Multiple endocrine neoplasia, type 2 | contraindication | 61808009 | |
| Pancreatitis | contraindication | 75694006 | DOID:4989 |
| C-cell hyperplasia of thyroid | contraindication | 237552009 | |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Medullary thyroid carcinoma | contraindication | 255032005 | DOID:3973 |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.06 | acidic |
| pKa2 | 3.31 | acidic |
| pKa3 | 3.67 | acidic |
| pKa4 | 3.82 | acidic |
| pKa5 | 4.11 | acidic |
| pKa6 | 4.44 | acidic |
| pKa7 | 9.65 | acidic |
| pKa8 | 11.84 | acidic |
| pKa9 | 12.2 | acidic |
| pKa10 | 12.53 | acidic |
| pKa11 | 12.59 | acidic |
| pKa12 | 12.81 | acidic |
| pKa13 | 12.86 | acidic |
| pKa14 | 12.94 | acidic |
| pKa15 | 13.1 | acidic |
| pKa16 | 13.15 | acidic |
| pKa17 | 13.2 | acidic |
| pKa18 | 13.29 | acidic |
| pKa19 | 13.43 | acidic |
| pKa20 | 13.56 | acidic |
| pKa21 | 13.56 | acidic |
| pKa22 | 13.6 | acidic |
| pKa23 | 13.71 | acidic |
| pKa24 | 13.82 | acidic |
| pKa25 | 13.82 | acidic |
| pKa26 | 13.96 | acidic |
| pKa27 | 13.97 | acidic |
| pKa28 | 11.05 | Basic |
| pKa29 | 10.45 | Basic |
| pKa30 | 7.87 | Basic |
| pKa31 | 5.98 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 18MG/3ML (6MG/ML) | VICTOZA | NOVO NORDISK INC | N022341 | Jan. 25, 2010 | RX | SOLUTION | SUBCUTANEOUS | 9968659 | Jan. 9, 2037 | METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE |
| 18MG/3ML (6MG/ML) | SAXENDA | NOVO | N206321 | Dec. 23, 2014 | RX | SOLUTION | SUBCUTANEOUS | 9968659 | Jan. 9, 2037 | CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 18MG/3ML (6MG/ML) | SAXENDA | NOVO | N206321 | Dec. 23, 2014 | RX | SOLUTION | SUBCUTANEOUS | Dec. 4, 2023 | NEW PATIENT POPULATION |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucagon-like peptide 1 receptor | GPCR | AGONIST | EC50 | 10.20 | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D06404 | KEGG_DRUG |
| 4029703 | VANDF |
| C1456408 | UMLSCUI |
| CHEBI:71193 | CHEBI |
| CHEMBL4084119 | ChEMBL_ID |
| CHEMBL4524066 | ChEMBL_ID |
| D000069450 | MESH_DESCRIPTOR_UI |
| DB06655 | DRUGBANK_ID |
| 1133 | IUPHAR_LIGAND_ID |
| 8208 | INN_ID |
| 839I73S42A | UNII |
| 16134956 | PUBCHEM_CID |
| 1598264 | RXNORM |
| 166619 | MMSL |
| 232503 | MMSL |
| 26647 | MMSL |
| d07466 | MMSL |
| 010773 | NDDF |
| 444828003 | SNOMEDCT_US |
| 444907006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Saxenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2800 | INJECTION, SOLUTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Saxenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2800 | INJECTION, SOLUTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Saxenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-2800 | INJECTION, SOLUTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Xultophy 100/3.6 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0169-2911 | INJECTION, SOLUTION | 3.60 mg | SUBCUTANEOUS | BLA | 27 sections |
| Xultophy 100/3.6 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0169-2911 | INJECTION, SOLUTION | 3.60 mg | SUBCUTANEOUS | BLA | 27 sections |
| Xultophy 100/3.6 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0169-2911 | INJECTION, SOLUTION | 3.60 mg | SUBCUTANEOUS | BLA | 27 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-4060 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-4060 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0169-4060 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2853 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2853 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Saxenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4257 | INJECTION, SOLUTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4503 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |
| Victoza | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4503 | INJECTION | 6 mg | SUBCUTANEOUS | NDA | 28 sections |